These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9717064)

  • 1. Results of the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and an update on trials now in progress.
    Ericsson CG
    Eur Heart J; 1998 Jul; 19 Suppl H():H37-41. PubMed ID: 9717064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Hamsten A; Nilsson J
    Drugs Exp Clin Res; 1995; 21(3):105-24. PubMed ID: 7555614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) Study.
    Goldbourt U; Brunner D; Behar S; Reicher-Reiss H
    Eur Heart J; 1998 Jul; 19 Suppl H():H42-7. PubMed ID: 9717065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():257-63. PubMed ID: 9211018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial.
    Goldenberg I; Boyko V; Tennenbaum A; Tanne D; Behar S; Guetta V
    Arch Intern Med; 2009 Mar; 169(5):508-14. PubMed ID: 19273782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients.
    Ericsson CG; Hamsten A; Nilsson J; Grip L; Svane B; de Faire U
    Lancet; 1996 Mar; 347(9005):849-53. PubMed ID: 8622389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A
    Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).
    Ruotolo G; Ericsson CG; Tettamanti C; Karpe F; Grip L; Svane B; Nilsson J; de Faire U; Hamsten A
    J Am Coll Cardiol; 1998 Nov; 32(6):1648-56. PubMed ID: 9822092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 11. Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).
    Goldenberg I; Goldbourt U; Boyko V; Behar S; Reicher-Reiss H;
    Am J Cardiol; 2006 Feb; 97(4):466-71. PubMed ID: 16461038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of restenosis by bezafibrate after successful coronary angioplasty.
    Ishiwata S; Nakanishi S; Nishiyama S; Seki A
    Coron Artery Dis; 1995 Nov; 6(11):883-9. PubMed ID: 8696533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment.
    Ruotolo G; Båvenholm P; Brismar K; Eféndic S; Ericsson CG; de Faire U; Nilsson J; Hamsten A
    J Am Coll Cardiol; 2000 Mar; 35(3):647-54. PubMed ID: 10716467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
    Arcavi L; Behar S; Caspi A; Reshef N; Boyko V; Knobler H
    Am Heart J; 2004 Feb; 147(2):239-45. PubMed ID: 14760320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy.
    Rembold CM
    J Fam Pract; 1996 Jun; 42(6):577-86. PubMed ID: 8656168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin Alone and in Combination Treatment.
    Cortellaro M; Cofrancesco E; Boschetti C; Cortellaro F; Mancini M; Mariani M; Paoletti R
    Thromb Haemost; 2000 Apr; 83(4):549-53. PubMed ID: 10780315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial.
    Goldenberg I; Benderly M; Goldbourt U;
    J Am Coll Cardiol; 2008 Jan; 51(4):459-65. PubMed ID: 18222357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome.
    Tenenbaum A; Motro M; Fisman EZ; Tanne D; Boyko V; Behar S
    Arch Intern Med; 2005 May; 165(10):1154-60. PubMed ID: 15911729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate.
    Tenenbaum A; Fisman EZ; Boyko V; Benderly M; Tanne D; Haim M; Matas Z; Motro M; Behar S
    Arch Intern Med; 2006 Apr; 166(7):737-41. PubMed ID: 16606809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fibrates in the secondary prevention of ischemic cardiopathy].
    Posadas Romero C
    Arch Cardiol Mex; 2001; 71 Suppl 1():S139-41. PubMed ID: 11565320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.